Cinrebafusp alfa 产品活性：Cinrebafusp alfa (PRS 343) 是一种高亲和力的 CD137/HER2 双特异性抗钙蛋白药物。Cinrebafusp alfa 结合重组人 HER2 (Kd=0.3 nM) 和人单体 CD137 (4-1BB; Kd=5 nM)。Cinrebafusp alfa 通过肿瘤定位的 HER2 依赖性 4-1BB 聚集和激活促进 T 细胞共刺激，进一步增强 T 细胞受体介导的活性并导致肿瘤破坏。Cinrebafusp alfa 具有用于 HER2+ 实体瘤研究的潜力。 产品来源： https://www.medchemexpress.cn/cinrebafusp-alfa.html 研究领域：JAK/STAT Signaling | Protein Tyrosine Kinase/RTK | Apoptosis 作用靶点：EGFR | TNF Receptor In Vitro: Cinrebafusp alfa (PRS 343) binds HER2-expressing MCF-7 cells with an EC50 of 7.4 nmol/L and binds to CHO cells transfected with human 4-1BB with an EC50 of 6.2 nmol/L in a FACS assay. In Vivo: Cinrebafusp alfa (PRS 343; 0.2-10 mg/kg; IV; once weekly; for 20 day) leads to tumor growth inhibition and has a dose-dependent increase of tumor-infiltrating lymphocytes in a humanized mouse model engrafted with HER2-positive SK-OV-3 tumor cells. Cinrebafusp alfa (10 mg/kg; IV; single dose) has the terminal elimination half-life of >14 days in male CD-1 mice. Cinrebafusp alfa (3 mg/kg; IV; single dose) has the terminal elimination half-life approximately 4 days in male cynomolgus monkeys. 相关产品：Osimertinib | Trastuzumab | Resatorvid | Gefitinib | Cetuximab | Erlotinib | Afatinib | Trastuzumab deruxtecan | Lapatinib | Shikonin | AG490 | Genistein | Infliximab | Neratinib | Trastuzumab emtansine | Tucatinib | Fisetin | Adalimumab | Etanercept | N-Formyl-Met-Leu-Phe | Dacomitinib | AG-1478 | Pertuzumab | Apremilast | Disitamab vedotin | R-7050 | Theophylline | QNZ 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。